BHC
NYSE · Pharmaceuticals
Bausch Health Cos Inc
$8.15
+0.19 (+2.39%)
Financial Highlights (FY 2026)
Revenue
14.67B
Net Income
224.39M
Gross Margin
70.6%
Profit Margin
1.5%
Rev Growth
+8.1%
D/E Ratio
44.72
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 70.6% | 70.6% | 33.3% | 33.3% |
| Operating Margin | 19.2% | 17.3% | 27.5% | 31.6% |
| Profit Margin | 1.5% | 1.5% | 29.0% | 22.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 14.67B | 13.57B | 415.01M | 424.70M |
| Gross Profit | 10.37B | 9.59B | 138.21M | 141.43M |
| Operating Income | 2.82B | 2.35B | 114.09M | 134.41M |
| Net Income | 224.39M | 186.80M | 120.28M | 97.22M |
| Gross Margin | 70.6% | 70.6% | 33.3% | 33.3% |
| Operating Margin | 19.2% | 17.3% | 27.5% | 31.6% |
| Profit Margin | 1.5% | 1.5% | 29.0% | 22.9% |
| Rev Growth | +8.1% | +8.1% | +10.0% | +0.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.14B | 2.14B | 706.86M | 615.00M |
| Total Equity | 47.77M | 47.77M | 1.48B | 1.79B |
| D/E Ratio | 44.72 | 44.72 | 0.48 | 0.34 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.25B | 3.74B | 156.90M | 174.68M |
| Free Cash Flow | — | — | 115.51M | 151.31M |